

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number  
**WO 02/055017 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**  
(21) International Application Number: PCT/US01/43871  
(22) International Filing Date:  
19 November 2001 (19.11.2001)  
(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
09/718,195 21 November 2000 (21.11.2000) US  
(71) Applicant (for all designated States except US): **WAKE  
FOREST UNIVERSITY** [US/US]; Medical Center  
Boulevard, Winston-Salem, NC 27157 (US).

(81) Designated States (*national*): AE, AG, AI, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

(72) Inventors; and  
(75) Inventors/Applicants (for US only): **KAMMER, Gary,  
M.** [US/US]; 2424 Sattsgate Drive, Lewisville, NC 27023  
(US). **MISHRA, Nilamadhab** [IN/US]; 1182 Stixfield  
Court, Winston-Salem, NC 27101 (US).  
(74) Agent: **SIBLEY, Kenneth, D.**; Myers Bigel Sibley &  
Sajovec, P.O. Box 37428, Raleigh, NC 27627 (US).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



**WO 02/055017 A2**

(54) Title: METHOD OF TREATING AUTOIMMUNE DISEASES

(57) Abstract: A method of treating an autoimmune disease (for example, Systemic Lupus Erythematosus) comprises administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof. Methods of screening compounds useful for the treatment of autoimmune disease are also disclosed.

5

**METHOD OF TREATING AUTOIMMUNE DISEASES**

Gary M. Kammer and Nilamadhab Mishra

10

**Statement Of Federal Support**

This invention was made possible with government support under grant numbers R01 AR39501 from the National Institute of Health. The United States government has certain rights to this invention.

15

**Field Of The Invention**

The present invention relates to methods for the treatment of autoimmune diseases such as systemic lupus erythematosus.

**Background of the Invention**

20

The hallmark of the aberrant cellular immune response in systemic lupus erythematosus (SLE) is T cell dysfunction (A. K. Dayal and G. M. Kammer, *Arthritis Rheum.* **39**, 23 (1996); D. A. Horwitz, et al., in *Dubois' Lupus Erythematosus.*, D. J. Wallace and B. H. Hahn, Eds. (Williams & Wilkins, Baltimore, 1997), chap. 10). An imbalance exists between exaggerated helper function and deficient cytotoxic/suppressor activity that promotes inappropriate B cell overproduction of immunoglobulins (Ig). The resulting polyclonal hypergammaglobulinemia is comprised of natural antibodies and pathogenic autoantibodies, including anti-native DNA. Formation of complement-fixing immune complexes *in situ* or their deposition on vascular endothelium, such as the renal glomerulus, initiates a chronic inflammatory response that leads to irreparable parenchymal damage, ultimately resulting in end-organ failure (R. P. Kimberly, in *Arthritis and Allied Conditions: A Textbook of Rheumatology*, W. J. Koopman, Ed. (Williams & Wilkins, Baltimore, 1997), chap. 27). Moreover, T cell dysfunctions predispose to recurrent, often life-threatening infections (A. G. Iliopoulos and G. C. Tsokos, *Sem.Arthritis Rheum.* **25**, 318 (1996); C. A. Hunter and S. L. Reiner, *Curr.Opin.Immunol.* **12**, 413 (2000)).

35

Two principal defects of T cell function in SLE are augmented expression of cell surface receptors and altered production of cytokines. CD40 ligand (CD154) expression is significantly increased and prolonged on both CD4<sup>+</sup> helper (Th) and CD8<sup>+</sup> cytotoxic/suppressor (Tc) subpopulations (M. Koshy, et al., *J.Clin.Invest.* **98**, 826 (1996); A. Desai-Mehta, et al, *J.Clin.Invest.* **97**, 2063 (1996)). This prolonged over-expression may be pathophysiologically significant, for binding of CD154 on Th cells to CD40 on B cells promotes B cell activation and may drive the polyclonal hypergammaglobulinemia. Moreover, Th2 cells over-produce IL-10 whereas Th1 cells under-produce IFN- $\gamma$ . Heightened levels of IL-10 may profoundly modify the cellular immune response by (a) downregulating both IFN- $\gamma$  and IL-2 production by Th1 cells; (b) inhibiting IL-12 generation and down-regulating expression of IL-12 receptors on Th1 cells; (c) up-regulating *bcl-2* expression and preventing apoptosis of activated T cells; and, (d) promoting B cell growth, differentiation and autoantibody production. By contrast, deficient IFN- $\gamma$  may significantly hinder cellular immunity in SLE by both impairing Tc-dependent cytotoxicity and altering antigen-presentation (B. S. Handwerger, et al., in *Lupus: Molecular and Cellular Pathogenesis*, G. M. Kammer and G. C. Tsokos, Eds. (Humana Press, Totowa, N.J., 1999) ,chap. 21).

While several treatments for SLE and other autoimmune diseases have been developed, none are entirely satisfactory. Hence, there remains a need for new ways to treat autoimmune diseases such as SLE.

#### **Summary of the Invention**

A first aspect of the present invention is a method of treating an autoimmune disease in a subject in need thereof, comprising administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof.

A second aspect of the present invention is a method of treating Systemic Lupus Erythematosus in a subject in need thereof, comprising administering to that subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof.

A still further aspect of the present invention is the use of an active agent as described above for the preparation of a medicament for the treatment of a disorder as described above.

Still further aspects of the present invention are methods of screening candidate compounds for activity in treating autoimmune diseases such as systemic lupus erythematosus.

Histone deacetylases (HDACs) are enzymes that deacetylate specific lysine  
5 residues of histone amino-terminal tail domains and certain non-histone substrates. Current evidence implicates the deacetylases in transcriptional repression (T. Kouzarides, *Curr.Opin.Genet.Dev.* **9**, 40 (1999); W. D. Cress and E. Seto, *J.Cell.Physiol.* **184**, 1 (2000)). Complexed with Sin3 and Mi2 transcriptional co-repressor proteins, HDAC/Sin3 and HDAC/Mi2 associate with other DNA-binding  
10 proteins, such as Ikaros (W. D. Cress and E. Seto, *J.Cell.Physiol.* **184**, 1 (2000); J. Kim et al., *Immunity* **10**, 345 (1999)). These deacetylase complexes appear to limit the accessibility of transcription factors to the promoter by closely juxtaposing the nucleosome to DNA. Of the eight human HDACs discovered (W. D. Cress and E. Seto, *J.Cell.Physiol.* **184**, 1 (2000)), to date only HDACs1-3 have been identified in T  
15 cells (F. Dangond et al., *Biochem.Biophys.Res.Comm.* **242**, 648 (1998)). During T cell activation, HDAC/Mi2 complexes are recruited to regions of the heterochromatin by Ikaros and modulate gene expression (J. Kim et al., *Immunity* **10**, 345 (1999); Koipally, J., et al. *EMBO J* **18**, 3090 (1999)). Trichostatin A, an HDAC inhibitor (M. Yoshida, et al., *J.Biol.Chem.* **265**, 17174 (1990); S. Finnin et al., *Nature* **401**, 188  
20 (1999)), blocks deacetylase activity and shifts the equilibrium toward histone acetylation. By acetylating histones, chromatin is remodeled, promoting access of DNA-binding transcription factors and the transcriptional machinery to promoter/enhancer regions (W. D. Cress and E. Seto, *J.Cell.Physiol.* **184**, 1 (2000); R. D. Kornberg and Y. Lorch, *Curr.Opin.Gen.Dev.* **9**, 148 (1999)). Acetylation may  
25 mediate positive or negative regulatory events that depend upon the particular gene (Z. W. Sun and M. Hampsey, *Genetics* **152**, 921 (1999)). Thus, promoter regions that are ordinarily silenced can then be derepressed whereas those that are expressed can be repressed. However, the use of histone deacetylase inhibitors or other histone hyperacetylating agents in the treatment of autoimmune diseases such as SLE has not  
30 heretofore been suggested or disclosed.

The present invention is explained in greater detail in the specification set forth below.

### **Brief Description of the Drawings**

**Figure 1A** shows the down-regulation of CD154 transcript levels by TSA. Increasing concentrations of TSA (0-1000 ng/ml) progressively inhibit expression of CD154 mRNA relative to expression of GAPDH mRNA.

5        **Figure 1B** shows a graphic depiction of a densitometric scan of the gel in **Figure 1A**. This graph depicts the percent change of CD154 mRNA expression with increasing concentrations of TSA over 24 hr. GAPDH mRNA expression is stable and unchanged in the presence of TSA.

10        **Figure 1C** shows CD154 transcript levels in T cells incubated in the absence or presence of 1000 ng/ml TSA over 18 hr. T cells were then stimulated with 20 ng/ml PMA + 0.5  $\mu$ M IO for intervals to 24 hr. CD154 mRNA expression relative to GAPDH mRNA expression is shown.

**Figure 1D** shows a graphic depiction of the percent change in CD154 mRNA expression over time in the absence (filled circles) or presence (open circles) of TSA.

15        **Figure 1E** shows flow cytometric analysis of CD154 and CD3- $\epsilon$  expression on SLE T cells. T cells were cultured in the absence or presence of 1000 ng/ml TSA for 18 hr, and subsequently activated with 20 ng/ml PMA + 0.5  $\mu$ M IO for 24 hr. The abscissa denotes the number of cells and ordinate the intensity of cell fluorescence signal. Statistical analyses were performed by paired Student's *t* test or one-way  
20 ANOVA.

**Figure 2A** shows the down-regulation of IL-10 levels by TSA. Increasing concentrations of TSA (0-1000 ng/ml) progressively inhibit expression of IL-10 mRNA relative to expression of GAPDH mRNA.

25        **Figure 2B** shows a graphic depiction of a densitometric scan of the gel in **Figure 2A**. This graph depicts the percent change of IL-10 transcript expression with increasing concentrations of TSA over 24 hr.

**Figure 2C** shows IL-10 and GAPDH transcripts from T cells of three SLE subjects. Transcripts from freshly isolated T cells are shown in lanes 1, 4, and 7. Transcripts from T cells cultured for 18 hr in the absence or presence of 1000 ng/ml  
30 TSA are shown in lanes 2, 5, 8 and 3, 6, and 9, respectively.

**Figure 2D** shows a graphic depiction of a densitometric scan of the gel in **Figure 2C**. This graph shows the percent change in IL-10 mRNA from SLE T cells cultured in the absence or presence of 1000 ng/ml TSA.

**Figure 2E** illustrates the inhibition of IL-10 secretion by increasing concentrations of TSA over 24 hr.

**Figure 2F** depicts the percent change of IL-10 production over time. Statistical analysis was performed by paired Student's *t* test.

5        **Figure 3A** shows the up-regulation of IFN- $\gamma$  transcript by TSA. T cells were incubated in the absence or presence of 1000 ng/ml TSA over 18 hr. T cells were then stimulated with 20 ng/ml PMA + 0.5  $\mu$ M IO for intervals to 24 hr. IFN- $\gamma$  mRNA expression relative to GAPDH mRNA expression is shown.

10        **Figure 3B** shows a graphic depiction of a densitometric scan of the gel in **Figure 3A**. This graphs depicts the fold increase of IFN- $\gamma$  mRNA in cells cultured in the absence (filled circles) or presence (open circles) of 1000 ng/ml TSA during intervals to 24 hr.

15        **Figure 3C** shows IFN- $\gamma$  protein levels from T cells cultured in the absence or presence of 1000 ng/ml TSA for 24 hr, and then stimulated with 20 ng/ml PMA + 0.5  $\mu$ M IO for 24 hr. The graph shows the fold increase of IFN- $\gamma$  protein secretion. Statistical analyses were performed by paired Student's *t* test or one-way ANOVA.

#### **Detailed Description of Preferred Embodiments**

20        The term "treat" as used herein refers to any type of treatment that imparts a benefit to a patient afflicted with a disease, including improvement in the condition of the patient (*e.g.*, in one or more symptoms), delay in the progression of the disease, etc.

25        The term "pharmaceutically acceptable" as used herein means that the compound or composition is suitable for administration to a subject to achieve the treatments described herein, without unduly deleterious side effects in light of the severity of the disease and necessity of the treatment.

30        Active compounds of the present invention may optionally be administered in conjunction with other compounds useful in the treatment of the autoimmune disease such as SLE. The other compounds may optionally be administered concurrently. As used herein, the word "concurrently" means sufficiently close in time to produce a combined effect (that is, concurrently may be simultaneously, or it may be two or more events occurring within a short time period before or after each other).

As used herein, the administration of two or more compounds "concurrently"

or "in combination" means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other. The two compounds may be administered simultaneously or sequentially. Simultaneous administration may be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.

Autoimmune diseases with which the present invention is concerned include, but are not limited to, Rheumatoid Arthritis, Sjogren's disease, Polymyositis, Dermatomyositis, and Systemic Lupus Erythomatosus. A particularly preferred application of the present invention is in the treatment of Systemic Lupus erythomatosus (SLE).

The present invention is primarily concerned with the treatment of human subjects, but the invention may also be carried out on animal subjects, particularly mammalian subjects such as mice, rats, dogs, cats, livestock and horses for veterinary purposes, and for drug screening and drug development purposes. In addition, the present invention may be used to treat animal subjects that are models of an autoimmune disease for drug screening and development purposes. A particular example of such a model is the mouse NZB/NZW F1 model of SLE.

## **1. Active compounds.**

Active compounds used to carry out the present invention are, in general, histone hyperacetylating agents, such as histone deacetylase inhibitors. Numerous such compounds are known. See, e.g., P. Dulski, Histone Deacetylase as Target for Antiprotozoal Agents, PCT Application WO 97/11366 (27 March 1997). Examples of such compounds include, but are not limited to:

A. Trichostatin A and its analogues, such as: Trichostatin A (TSA); and Trichostatin C (Koghe et al. 1998. *Biochem. Pharmacol.* 56:1359-1364) (Trichostatin B has been isolated but not shown to be an HDAC inhibitor).

B. Peptides, such as: Oxamflati [(2E)-5-[3-[(phenylsulfonyl) aminol phenyl]-pent-2-en-4-ynohydroxamic acid (Kim et al. *Oncogene*, 18:2461-2470 (1999)); Trapoxin A (TPX) – Cyclic Tetrapeptide (cyclo-(L-phenylalanyl-L-phenylalanyl-D-pipecoliny-L-2-amino- 8- oxo-9,10-epoxy-decanoyl)) (Kijima et al., *J. Biol. Chem.* 268, 22429-22435 (1993));

FR901228, Depsipeptide (Nakajima et al., *Ex. Cell Res.* **241**, 126-133 (1998));  
 FR225497, Cyclic Tetrapeptide (H. Mori et al., PCT Application WO  
 00/08048 (17 February 2000)); Apicidin, Cyclic Tetrapeptide [cyclo(N-O-  
 methyl-L-tryptophanyl-L-isoleuciny-D- pipecolinyl-L-2-amin o-8-  
 5 oxodecanoyl)] (Darkin-Rattray et al., *Proc. Natl. Acad. Sci. USA* **93**, 13143-  
 13147 (1996)); Apicidin 1a, Apicidin Ib, Apicidin Ic, Apicidin IIa, and  
 Apicidin IIb (P. Dulski et al., PCT Application WO 97/11366); HC-Toxin,  
 Cyclic Tetrapeptide (Bosch et al., *Plant Cell* **7**, 1941-1950 (1995)); WF27082,  
 Cyclic Tetrapeptide ( PCT Application WO 98/48825); and chlamydocin  
 10 (Bosch et al., *supra*).

C. Hydroxamic Acid-Based Hybrid Polar Compounds (HPCs), such  
as: Salicylihydroxamic Acid (SBHA) (Andrews et al., *International J.*  
*Parasitology* **30**, 761-768 (2000)); Suberoylanilide Hydroxamic Acid (SAHA)  
 (Richon et al., *Proc. Natl. Acad. Sci. USA* **95**, 3003-3007 (1998)); Azelaic  
 15 Bishydroxamic Acid (ABHA) (Andrews et al., *supra*); Azelaic-1-  
 Hydroxamate-9-Anilide (AAHA) (Qiu et al., *Mol. Biol. Cell* **11**, 2069-2083  
 (2000)); M-Carboxycinnamic Acid Bishydroxamide (CBHA) (Ricon et al.,  
*supra*); 6-(3-Chlorophenylureido)carpoic Hydroxamic Acid (3-Cl-UCHA)  
 (Richon et al., *supra*); MW2796 (Andrews et al., *supra*); and MW2996  
 20 (Andrews et al., *supra*). Note that analogs not effective as HDAC Inhibitors  
 are: Hexamethylene bisacetamide (HBMA) (Richon et al. 1998, PNAS,  
 95:3003-3007); and Diethyl bix(pentamethylene-N,N-dimethylcarboxamide)  
 malonate (EMBA) (Richon et al. 1998, PNAS, 95:3003-3007).

D. Short Chain Fatty Acid (SCFA) Compounds, such as: Sodium  
 25 Butyrate (Cousens et al., *J. Biol. Chem.* **254**, 1716-1723 (1979)); Isovalerate  
 (McBain et al., *Biochem. Pharm.* **53**:1357-1368 (1997)); Valerate (McBain et  
 al., *supra*); 4-Phenylbutyrate (4-PBA) (Lea and Tulsyan, *Anticancer Research*,  
**15**, 879-873 (1995)); Phenylbutyrate (PB) (Wang et al., *Cancer Research*, **59**,  
 2766-2799 (1999)); Propionate (McBain et al., *supra*); Butyrimide (Lea and  
 30 Tulsyan, *supra*); Isobutyramide (Lea and Tulsyan, *supra*); Phenylacetate (Lea  
 and Tulsyan, *supra*); 3-Bromopropionate (Lea and Tulsyan, *supra*); and  
 Tributyrin (Guan et al., *Cancer Research*, **60**, 749-755 (2000)).



E. Benzamide derivatives, such as: MS-27-275 [N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl) aminomethyl] benzamide] (Saito et al., *Proc. Natl. Acad. Sci. USA* 96, 4592-4597 (1999)); and 3'-amino derivative of MS-27-275 (Saito et al., *supra*).

5        F. Other inhibitors, such as: Depudecin [its analogues (mono-MTM-depudecin and depudecin-bisether) do not inhibit HDAC] (Kwon et al. 1998. PNAS 95:3356-3361); and Scriptaid (Su et al. 2000 Cancer Research, 60:3137-3142).

The active compounds disclosed can, as noted above, be prepared in the form  
10 of their pharmaceutically acceptable salts. Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects. Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic  
15 acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; (b) salts formed from elemental anions such as  
20 chlorine, bromine, and iodine, and (c) salts derived from bases, such as ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium, and salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine.

25    **2. Compounds for Concurrent Administration.**

The active compound histone hyperacetylating agents described herein may be administered concurrently with other active compounds known for the treatment of autoimmune diseases (such as systemic lupus erythematosus). Examples of such other active compounds include, but are not limited to: (i) corticosteroids such as  
30 prednisolone sodium phosphate, such as Pediapred® ; methylprednisolone, such as Medrol®; prednisone, such as Deltasone® or Orasone®; and dexamethasone, such as Decadron® Tablets; (ii) steroids such as lynestrenol – a progestagen; desogestrel – a progestagen; ethylestrenol – an anabolic steroid; and tibolone – a weak progestational,

anabolic, androgenic steroid (H.A. Verheul et al. *Clin. Immunol. Immunopathol.* **38**:198-208 (1986)); and exogenous DHEA – dehydroepiandrosterone – (T. Suzuki et al. *Clin. Exp. Immunol.* **99**:251-255 (1995)); and (iii) other compounds such as hydroxchloroquine sulfate, such as Plaquenil®; H1-A (isolated from *Cordyceps sinensis*) (L.Y. Yang, et al. *J. Lab Clin. Med.* **134**:492-500 (1999)); sulfasalazine (a.k.a. Salazosulfapyridine) (E. Delaporte et al. *Ann. Dermatol. Venereol.* **124**:151-156 (1997)); anti-ICAM-1 – murine antiintercellular adhesion molecule-1 (R.L. Brey et al. *Lupus* **6**:645-651 (1997)); MX-68 – upolyglutamable antifolate (M. Mihara et al. *Int. Arch. Allergy Immunol.* **13**:454-459 (1997)); FK506 – (K. Yamamoto et al. *Immunology* **69**:222-227 (1990)); AS101 – organotellurium compound – (J. Alcocer-Varela et al. *Clin. Exp. Immunol.* **77**:319-323 (1989)); HWA-131 – (3-(3,5-ditert.butyl-4-hydroxyphenyl)-7H-thiazolo(3,2-b)(1,2,4)triaz in-7-one) (R.R. Bartlett et al. *Drugs Exp. Clin. Res.* **15**:521-526 (1989)); and Auranofin – Oral gold compound – (K. Dalziel et al. *Br. J. Dermatol.* **115**:211-216 (1986)).

The foregoing may be administered in the same formulation and/or by the same route of administration, or by a different formulation and/or different route of administration, as the active agent histone hyperacetylating agents described herein, in their conventional dosages or dosages which can be determined from the conventional dosages.

20

### **3. Pharmaceutical formulations.**

The active compounds described above may be formulated for administration in a pharmaceutical carrier in accordance with known techniques. See, e.g., Remington, *The Science And Practice of Pharmacy* (9<sup>th</sup> Ed. 1995). In the manufacture of a pharmaceutical formulation according to the invention, the active compound (including the physiologically acceptable salts thereof) is typically admixed with, *inter alia*, an acceptable carrier. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.01 or 0.5% to 95% or 99% by weight of the active compound. One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of

30

the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.

The formulations of the invention include those suitable for oral, rectal, topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, intraperitoneal, intravenous, etc.), topical (e.g., both skin and mucosal surfaces, including airway surfaces) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active compound which is being used.

Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.

Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the active compound in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations of the present invention suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the active compound, which preparations are preferably isotonic with the blood of the intended recipient.

These preparations may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents. The formulations may be presented in unit\dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. For example, in one aspect of the present invention, there is provided an injectable, stable, sterile composition comprising an active compound as described above, or a salt thereof, in a unit dosage form in a sealed container. The compound or salt is provided in the form of a lyophilizate which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into a subject. The unit dosage form typically comprises from about 10 mg to about 10 grams of the compound or salt. When the compound or salt is substantially water-insoluble, a sufficient amount of emulsifying agent which is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.

Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (*see, for example, Pharmaceutical Research* 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. Suitable formulations

comprise citrate or bis\tris buffer (pH 6) or ethanol/water and contain from 0.1 to 0.2M active ingredient.

Further, the present invention provides liposomal formulations of the compounds disclosed herein and salts thereof. The technology for forming liposomal suspensions is well known in the art. When the compound or salt thereof is an aqueous-soluble salt, using conventional liposome technology, the same may be incorporated into lipid vesicles. In such an instance, due to the water solubility of the compound or salt, the compound or salt will be substantially entrained within the hydrophilic center or core of the liposomes. The lipid layer employed may be of any conventional composition and may either contain cholesterol or may be cholesterol-free. When the compound or salt of interest is water-insoluble, again employing conventional liposome formation technology, the salt may be substantially entrained within the hydrophobic lipid bilayer which forms the structure of the liposome. In either instance, the liposomes which are produced may be reduced in size, as through the use of standard sonication and homogenization techniques.

Of course, the liposomal formulations containing the compounds disclosed herein or salts thereof, may be lyophilized to produce a lyophilizate which may be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.

Other pharmaceutical compositions may be prepared from the water-insoluble compounds disclosed herein, or salts thereof, such as aqueous base emulsions. In such an instance, the composition will contain a sufficient amount of pharmaceutically acceptable emulsifying agent to emulsify the desired amount of the compound or salt thereof. Particularly useful emulsifying agents include phosphatidyl cholines, and lecithin.

In addition to active compounds or their salts, the pharmaceutical compositions may contain other additives, such as pH-adjusting additives. In particular, useful pH-adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate. Further, the compositions may contain microbial preservatives. Useful microbial preservatives include methylparaben, propylparaben, and benzyl alcohol. The microbial preservative is typically employed when the formulation is placed in a vial designed for multidose use. Of course, as indicated, the

pharmaceutical compositions of the present invention may be lyophilized using techniques well known in the art.

#### **4. Dosage and routes of administration.**

5           As noted above, the present invention provides pharmaceutical formulations comprising the active compounds (including the pharmaceutically acceptable salts thereof), in pharmaceutically acceptable carriers for oral, rectal, topical, buccal, parenteral, intramuscular, intradermal, or intravenous, and transdermal administration.

10           The therapeutically effective dosage of any specific compound, the use of which is in the scope of present invention, will vary from compound to compound and patient to patient, and will depend upon factors such as the age, weight, and condition of the patient and the route of delivery. As a general proposition, a dosage from about 0.01 or 0.1 to about 50, 100 or 500 mg/kg will have therapeutic efficacy, with all weights being calculated based upon the weight of the active compound, including the cases where a salt is employed. Toxicity concerns at the higher level may restrict  
15 intravenous dosages to a lower level such as up to about 10 mg/kg, with all weights being calculated based upon the weight of the active base, including the cases where a salt is employed. A dosage from about 10 mg/kg to about 50 mg/kg may be employed for oral administration. Typically, a dosage from about 0.5 mg/kg to 5  
20 mg/kg may be employed for intramuscular injection. Preferred dosages are 1  $\mu$ mol/kg to 50  $\mu$ mol/kg, and more preferably 22  $\mu$ mol/kg and 33  $\mu$ mol/kg of the compound for intravenous or oral administration. The duration of the treatment is usually once per day for a period of two to three weeks or until the condition is essentially controlled. Lower doses given less frequently can be used prophylactically to prevent or reduce  
25 the incidence of recurrence of the disorder, or the severity of symptoms. For example, the trichostatin analog SAHA is being given in phase I clinical trials for cancer by an intravenous route.

#### **5. Screening Assays.**

30           The present invention also provides screening assays for identifying compounds useful, or potentially useful, in the treatment of autoimmune diseases such as SLE. Such assays may be carried out in accordance with known techniques, such as the formats described in P. Dulski, PCT Application WO97/11366 (27 March

1997).

One method of screening compounds for activity in treating an autoimmune disease, comprises

5 (a) contacting a histone deacetylase, or an extract containing histone deacetylase with (i) a known amount of a labeled compound that interacts with a histone deacetylase; and (ii) a known dilution of a test compound or natural product extract; and then

10 (b) determining the inhibition of interaction of said labeled compound with said histone deacetylase induced by said test compound, where the inhibition of interaction of said labeled compound with said histone deacetylase indicates said compound or extract is a candidate for the treatment of an autoimmune disease.

The histone deacetylase is preferably a mammalian (e.g., mouse, rat, rabbit) histone deacetylase, and is most preferably a human histone deacetylase. The labeled  
15 compound may be any of the active agents described above, labeled with a suitable detectable group such as tritium. In general, the labeled compound will be one which binds to histone deacetylase or is a substrate of histone deacetylase. The test compound may be of any source, such as an oligomer or a non-oligomer from a combinatorial library, or a rationally synthesized candidate compound. Extracts may  
20 be obtained from any suitable source, such as plant extracts obtained through techniques known in traditional, folk or herbal medicine. The determining step may be carried out qualitatively or quantitatively by any suitable means, such as by Scatchard analysis with a series of serial dilutions of the test compound or extract.

25 In another embodiment, a method of screening compounds for activity in treating an autoimmune disease such as SLE comprises:

(a) contacting an intact host cell *in vivo* or *in vitro* with a test compound or a natural product extract; and then

30 (b) determining the level of histone acetylation in said cell, wherein elevated levels of histone acetylation indicates said compound or extract is a candidate for the treatment of an autoimmune disease.

Where the contacting step is carried out *in vivo* (e.g., as in the course of a clinical trial) the compound is administered to a suitable subject carrying the cell by any of the same techniques described above for administering active agents, and the cell (or

collection of cells) subsequently collected from the subject for use in the determining step. The cell (or subject) is preferably mammalian (*e.g.*, a mouse, rat or rabbit cell) and in one particularly preferred embodiment is human. Lymphocytes are particularly preferred cells. The subject may be one afflicted with an autoimmune disease such as

5 SLE (including models of such a disease), or may be a normal (or unafflicted) subject. Elevated levels may be determined by comparison to an untreated, control subject or cell, by comparison to levels found in the the same subject or cell or cell population prior to treatment, etc. Assays for histone levels may be carried out by any suitable technique, with histone level assays being known to those skilled in the art.

10 The examples, which follow, are set forth to illustrate the present invention, and are not to be construed as limiting thereof. In the following examples, hr means hour; min means minute; TSA means Trichostatin A; SLE means systemic lupus erythematosus; RT-PCR means reverse transcriptase polymerase chain reaction; IO means ionomycin, PMA means phorbol myristate acetate, ml means milliliter; ng

15 means nanogram; and all temperatures, unless otherwise indicated, are in degrees Celsius.

### EXAMPLE 1

#### Down-Regulation of CD154 Transcript and Protein Levels by TSA

Because SLE T cells are often activated (D. T. Y. Yu et al., *J.Exp.Med.* **151**,  
 20 91 (1980).), the up-regulation of CD154 and IL-10 and down-regulation of IFN- $\gamma$  may reflect skewed gene expression due to enhanced recruitment of HDACs to the promoters of these genes. The resulting dysequilibrium of acetylation might be expected to alter the chromatin structure of the promoters (R. D. Kornberg and Y. Lorch, *Curr.Opin.Gen.Dev.* **9**, 148 (1999)), thereby activating previously silenced

25 genes while repressing expressed genes. To determine if TSA can down-regulate CD154 transcript expression, T cells from eight SLE subjects were treated with increasing concentrations of TSA over 18 hr.

T cells were cultured in the absence or presence of increasing concentrations of TSA for 18 hr in 5% CO<sub>2</sub> at 37°C. RNA was isolated, cDNAs were prepared, and

30 RT-PCR was performed as previously detailed (D. Laxminarayana, et al., *J. Clin. Invest.* **92**, 2207 (1993)). The primers used were:

CD154: 5'-GAATCCTCAAATTGCGGCAC-3' (SEQ ID NO: 1) and  
 5'-CAGAAGGTGACTTGGCATAG-3'; (SEQ ID NO: 2)



GAPDH: 5'-GGTGAAGGTCGGAGTCAACG-3' (SEQ ID NO: 3) and  
 5'-CAAAGTTGTCATGGATGACC-3'; (SEQ ID NO: 4)  
 IL-10: 5'-TTGCCTGGTCCTCCTGACTG-3' (SEQ ID NO: 5) and  
 5'-GATGTCTGGGTCTTGGTTCT-3'; (SEQ ID NO: 6)  
 5 IFN- $\gamma$ : 5'-ATGAAATATACAAGTTATATCTTGGCTTT-3' (SEQ ID  
 NO: 7) and  
 5'-GATGCTCTTCGACCTCGAAACAGCAT-3'. (SEQ ID  
 NO: 8)

The reaction mixtures were subjected to 30 cycles of denaturation (94°C, 1  
 10 min) and annealing for 1 min at 53°C (CD154), 40°C (GAPDH) and 55°C (IL-10 and  
 IFN- $\gamma$ ). Extension was for 2 min at 72°C with a final extension of 7 min at 72°C using  
 a DNA thermal cycler (Perkin-Elmer).

**Figures 1A and 1B** demonstrate that TSA maximally inhibits CD154  
 transcript by 60%, but does not modify GAPDH mRNA expression. When SLE T  
 15 cells were activated with phorbol myristate acetate (PMA) and ionomycin (IO),  
 CD154 mRNA content increased 100%, peaked at 3 hr, and waned thereafter (**Figure  
 1C and 1D**). Under these conditions, however, GAPDH mRNA remained stable,  
 demonstrating that cellular activation also does not modify the expression of this  
 gene. By contrast, when T cells were preincubated with TSA for 18 hr and then  
 20 activated by PMA + IO over intervals to 24 hr, up-regulation of CD154 transcript was  
 significantly reduced throughout the entire time course compared to cells not exposed  
 to TSA (**Figure 1C and 1D**;  $P < 0.001$ ). Thus, in SLE T cells TSA significantly  
 down-regulates CD154 transcript expression.

In agreement with previous work (M. Koshy, et al., *J.Clin.Invest.* 98, 826  
 25 (1996); A. Desai-Mehta, et al., *J.Clin.Invest.* 97, 2063 (1996)), we find that an  
 increased proportion of SLE T cells express cell-surface CD154 compared to normal  
 and disease controls. To determine if TSA-dependent down-regulation of CD154  
 mRNA reduces surface expression of CD154, SLE T cells were treated for 18 hr with  
 TSA and the proportion of CD154<sup>+</sup> cells quantified by flow cytometry (E. Hagiwara,  
 et al., *Arthritis Rheum.* 39, 379 (1996)). Compared with untreated cells, TSA did not  
 30 effect any significant reduction of cell-surface CD154<sup>+</sup> cells over 24 hr (**Figure 1E**).  
 However, activation of SLE T cells with PMA + IO over 24 hr induced a new  
 population of CD154<sup>+</sup> cells that was completely inhibited when cells were pretreated

with TSA prior to activation (**Figure 1E**;  $P=0.005$ ). By contrast, CD3- $\epsilon$  expression remained stable under these varying conditions, indicating that TSA's effect on CD154 surface expression is not generalized (**Figure 1E**). T cells were stained with saturating concentrations of monoclonal FITC-anti-CD3 and PE anti-CD154 antibodies (Caltag Labs, Burlingame, CA) for 30 min at 4°C, and the proportion of cells expressing CD3- $\epsilon$  and CD154 was quantified. In sum, these experiments reveal that TSA down-regulates both CD154 mRNA and protein expression, but not GAPDH mRNA or CD3- $\epsilon$  expression, in SLE T cells.

10

## EXAMPLE 2

### Down-Regulation of IL-10 Transcript and Protein Levels by TSA

T cells from SLE subjects produce markedly increased amounts of IL-10 resulting in high serum levels of the cytokine (B. S. Handwerger, et al., in *Lupus: Molecular and Cellular Pathogenesis*, G. M. Kammer and G. C. Tsokos, Eds. (Humana Press, Totowa, N.J., 1999), chap. 21; E. Hagiwara, et al., *Arthritis Rheum.* 39, 379 (1996)). To determine whether TSA could down-regulate IL-10, a dose-response analysis was performed. Like CD154, increasing concentrations of TSA progressively inhibited IL-10 transcript expression (**Figure 2A and 2B**). In fact, based on sensitive reverse transcriptase-polymerase chain reaction (RT-PCR) analyses, no detectable IL-10 mRNA was identified at TSA concentrations of 700-800 ng/ml. By comparison, increasing concentrations of TSA did not modify GAPDH transcript expression (**Figure 2A and 2B**). As shown in **Figure 2C**, IL-10 transcripts were present in freshly isolated T cells (0 hr; lanes 1, 4, 7) and remained stable relative to GAPDH transcripts after culturing cells for 18 hr (lanes 2, 5, 8). However, when SLE T cells were cultured in the presence of TSA for 18 hr, no detectable IL-10 transcripts were identified (**Figure 2C**, lanes 3, 6, 9). When IL-10 transcripts from all eight SLE subjects were quantified relative to GAPDH transcripts, TSA inhibited expression of IL-10 mRNA by 71% (**Figure 2D**;  $P=0.029$ ). Treatment of T cells from eight SLE subjects over 18 hr with increasing concentrations of TSA resulted in a dose-dependent inhibition of IL-10 protein production that was maximal at 300 ng/ml of the inhibitor (**Figure 2E**). IL-10 and IFN- $\gamma$  protein production were quantified by ELISA (R & D Systems, Minneapolis, MN). Within 6 hr, TSA inhibited IL-10 production by 90%; at 24 hr, there was complete inhibition of IL-10 synthesis (**Figure**

2F). Thus, like CD154, TSA was able to block expression of IL-10 transcript, abolishing IL-10 production by SLE T cells.

### EXAMPLE 3

#### 5        Up-Regulation of IFN- $\gamma$ Transcript and Protein Levels by TSA

Low production of IFN- $\gamma$  by SLE T cells may reflect down-regulation of gene expression (B. S. Handwerger, et al., in *Lupus: Molecular and Cellular Pathogenesis*, G. M. Kammer and G. C. Tsokos, Eds. (Humana Press, Totowa, N.J., 1999), chap. 21; E. Hagiwara, et al., *Arthritis Rheum.* 39, 379 (1996)). To establish whether TSA can  
10 up-regulate IFN- $\gamma$  expression, SLE T cells were treated for 18 hr in the absence or presence of TSA. During that time, TSA induced a three-fold increase in IFN- $\gamma$  transcript compared to untreated cells (**Figure 3A**, lanes 1 and 7, and **Figure 3B**). When T cells were activated with PMA + IO in the absence of TSA, peak IFN- $\gamma$  transcript expression increased 13-fold at 1 hr over basal levels relative to GAPDH  
15 transcript, but waned thereafter. By contrast, activation of T cells in the presence of TSA induced a peak 37-fold increase in IFN- $\gamma$  mRNA at 6 hr over untreated cells relative to GAPDH (**Figure 3A and 3B**;  $P = 0.031$ ). Thus, TSA up-regulated expression of IFN- $\gamma$  transcripts in SLE T cells, yielding both a significantly increased and prolonged expression of the transcript.

20        This strong up-regulation of IFN- $\gamma$  transcript was reflected in significantly increased production of IFN- $\gamma$  protein by 24 hr. In the absence of stimulation, SLE T cells failed to produce any IFN- $\gamma$  over 72 hr. When T cells were activated with PMA + IO for 24 hr, IFN- $\gamma$  production increased about 24-fold. However, activation of T cells in the presence of TSA further enhanced IFN- $\gamma$  output by > 12-fold ( $P = 0.011$ )  
25 (**Figure 3C**). Taken together, these results demonstrate that TSA rapidly up-regulates both IFN- $\gamma$  transcript and protein production by SLE T cells.

The capacity of TSA to down-regulate cell surface CD154 and IL-10 production and to up-regulate IFN- $\gamma$  synthesis in SLE T cells provides new evidence in support of the proposition that skewed gene expression may be a fundamental  
30 mechanism underlying both the cellular and humoral immune dysregulation in this disease. That TSA was able to modify this altered gene expression *in vitro* also supports the concept that HDACs may be recruited to the promoter regions of these

genes where they effect skewed expression. Because the precise mechanism by which histone acetylation modifies transcription still remains uncertain (T. Kouzarides, *Curr.Opin.Genet.Dev.* 9, 40 (1999)), it is also unclear how inhibition of HDAC activity by TSA effects down-regulation of CD154 and IL-10 and up-regulation of IFN- $\gamma$  in SLE T cells. Notwithstanding, this capacity of TSA to modulate the expression of these genes appears to have the salutary effect of normalizing their protein expression *in vitro*. Because it can simultaneously target multiple genes involved in the immunopathogenesis of lupus, TSA would be an effective therapeutic agent.

10 In SLE, a chronic inflammatory response progressively destroys organ parenchyma, ultimately leading to irreversible end-organ failure such as end-stage renal disease. The immunopathogenesis of this chronic inflammatory process is in part due to the presence of complement-fixing immune complexes. Formation of pathogenic immune complexes depends on production of autoantibodies, such as anti-  
15 native DNA, that arise from dysregulated B cell clones (B. H. Hahn, *New Engl. J. Med.* 338, 1359 (1998)). Therefore, down-regulation of CD154 and IL-10 should eliminate both the sustained CD154-CD40 interaction as well as high cytokine levels that drive polyclonal hypergammaglobulinemia and autoantibody production, reducing immune complex formation. Similarly, up-regulation of IFN- $\gamma$  production  
20 might be expected to normalize an abnormal cellular immune response that predisposes to infections.

#### EXAMPLE 4

##### Suppression of Proteinuria and nitric oxide secretion

##### by HDIs in MRL/lpr/lpr mice *in vivo*

25 The effect of TSA on proteinuria and nitric oxide secretion and increased survival in 26 wk old MRL/lpr mice was examined. In this age group, MRL/lpr mice develop full-blown disease with evidence of proliferative immune-complex-mediated glomerulo-nephritis, vasculitis, arthritis, and massive lymphadenopathy. Most of the mice die by the age of 30 wk. Twelve 26 wk old MRL/lpr mice were randomized to  
30 receive 5mg/kg TSA in 50ul DMSO or 50ul DMSO as vehicle control by daily subcutaneous (s.c.) injection over the course of 4 weeks or until they show distress. The data for the first two weeks has been collected. Urine was collected for a 24hr time period on day 0, 7 and 14, and measured for protein and nitric oxide. Toxicity of

TSA is being assessed by monitoring body weight, infection, abnormal behavior and survival of treated mice. In this 2 week duration there have been no side effects noted. There were no deaths in control or TSA treated mice. In comparison to vehicle treated mice, six TSA treated mice have less proteinuria in day 7 and day 14

5 compared to day 0 (Table 1 and 2).

<b>Table 1</b> Proteinuria (ug/day) in vehicle treated mice			
MOUSE	DAY 0	DAY 7	DAY 14
1	41.2	32.7	40.1
2	8.1	4.27	3.15
3	2145	1869	3511
4	69.5	34.9	65.1
5	533	47	685
6	12.6	4.01	4.76

<b>Table 2</b> Proteinuria (ug/day) in TSA treated mice.			
MOUSE	DAY 0	DAY 7	DAY 14
1	16689	274	865
2	213	54	82
3	14420	4701	3081
4	107	80	25
5	5	9	10
6	964	340	242
7	10	4.6	4.3

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with  
 20 equivalents of the claims to be included therein.

**What is Claimed is:**

1. A method of treating an autoimmune disease in a subject in need thereof, comprising administering to said subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof.  
5
2. A method according to claim 1, wherein said histone hyperacetylating agent is a histone deacetylase inhibitor.
3. A method according to claim 1, wherein said histone hyperacetylating agent  
10 is selected from the group consisting of Trichostatin A and Trichostatin C.
4. A method according to claim 1, wherein said histone hyperacetylating agent is selected from the group consisting of Oxamflati, Trapoxin A, FR901228, Apicidin, HC-Toxin, WF27082, and Chlamydocin.
5. A method according to claim 1, wherein said histone hyperacetylating agent  
15 is selected from the group consisting of Salicylihydroxamic Acid, Suberoylanilide Hydroxamic Acid, and Azelaic Bishydroxamic Acid.
6. A method according to claim 1, wherein said histone hyperacetylating agent is selected from the group consisting of Azelaic-1-Hydroxamate-9-Anilide, M-  
20 Carboxycinnamic Acid Bishydroxamide, 6-(3-Chlorophenylureido)carpoic Hydroxamic Acid, MW2796, and MW2996.
7. A method according to claim 1, wherein said histone hyperacetylating agent is selected from the group consisting of Sodium Butyrate, Isovalerate, Valerate, 4-  
25 Phenylbutyrate, Phenylbutyrate, Propionate, Butrymide, Isobutyramide, Phenylacetate, 3-Bromopropionate, and Tributyrin.
8. A method according to claim 1, wherein said histone hyperacetylating agent is selected from the group consisting of MS-27-275  
30 and the 3'-amino derivative thereof.

9. A method according to claim 1, wherein said histone hyperacetylating agent is selected from the group consisting of Depudecin and Scriptaid.

5           10. A method according to claim 1, wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis, Sjogren's disease, polymyositis, and dermatomyositis.

10           11. A method of treating systemic lupus erythematosus in a subject in need thereof, comprising administering to said subject a treatment effective amount of a histone hyperactylating agent, or a pharmaceutically acceptable salt thereof.

15           12. A method according to claim 11, wherein said histone hyperacetylating agent is a histone deacetylase inhibitor.

          13. A method according to claim 11, wherein said histone hyperacetylating agent is selected from the group consisting of Trichostatin A and Trichostatin C.

20           14. A method according to claim 11, wherein said histone hyperacetylating agent is selected from the group consisting of Oxamflati, Trapoxin A, FR901228, Apicidin, HC-Toxin, WF27082, and Chlamydocin.

          15. A method according to claim 11, wherein said histone hyperacetylating agent is selected from the group consisting of Salicylihydroxamic Acid, Suberoylanilide Hydroxamic Acid, and Azelaic Bishydroxamic Acid.

25           16. A method according to claim 11, wherein said histone hyperacetylating agent is selected from the group consisting of Azelaic-1-Hydroxamate-9-Anilide, M-Carboxycinnamic Acid Bishydroxamide, 6-(3-Chlorophenylureido)carpoic Hydroxamic Acid, MW2796, and MW2996.

30           17. A method according to claim 11, wherein said histone hyperacetylating agent is selected from the group consisting of Sodium Butyrate, Isovalerate, Valerate,

4-Phenylbutyrate, Phenylbutyrate, Propionate, Butyramide, Isobutyramide, Phenylacetate, 3-Bromopropionate, and Tributyrin.

18. A method according to claim 11, wherein said histone  
5 hyperacetylating agent is selected from the group consisting of MS-27-275 and the 3'-amino derivative thereof.

19. A method according to claim 11, wherein said histone  
hyperacetylating agent is selected from the group consisting of Depudecin and  
10 Scriptaid.

20. A method of screening compounds for activity in treating an autoimmune disease, comprising:

(a) contacting a histone deacetylase, or an extract containing histone  
15 deacetylase with (i) a known amount of a labeled compound that interacts with a histone deacetylase; and (ii) a known dilution of a test compound or natural product extract; and

(b) determining the inhibition of interaction of said labeled compound with  
said histone deacetylase induced by said test compound, where the inhibition of  
20 interaction of said labeled compound with said histone deacetylase indicates said compound or extract is a candidate for the treatment of an autoimmune disease.

21 A method according to claim 20, wherein said histone deacetylase is  
mammalian histone deacetylase.  
25

22. A method according to claim 20, wherein said histone deacetylase is  
human histone deacetylase.

23. A method according to claim 20, wherein said labeled compound binds to  
30 histone deacetylase.

24. A method according to claim 20, wherein said labeled compound is a  
substrate of histone deacetylase.



25. A method according to claim 20, wherein said autoimmune disease is systemic lupus erythematosus.

5           26. A method of screening compounds for activity in treating an autoimmune disease, comprising:

          contacting an intact host cell with a test compound or a natural product extract; and then

          determining the level of histone acetylation in said cell, wherein elevated  
10       levels of histone acetylation indicates said compound or extract is a candidate for the treatment of an autoimmune disease.


27. A method according to claim 26, wherein said cell is a mammalian cell.

15           28. A method according to claim 26, wherein said cell is a human cell.

          29. A method according to claim 26, wherein said autoimmune disease is systemic lupus erythematosus.

20

Fig. 1



BEST AVAILABLE COPY

Fig. 2

BEST AVAILABLE COPY







Fig. 3



RECEIVED COPY

9151-10WO.ST25.txt  
SEQUENCE LISTING

&lt;110&gt; Wake Forest University

Kammer, Gary M.

Mishra, Nilamadhab

&lt;120&gt; Method of Treating Autoimmune Diseases

&lt;130&gt; 9151.10WO

&lt;150&gt; US 09/718,195

&lt;151&gt; 2000-11-21

&lt;160&gt; 8

&lt;170&gt; PatentIn version 3.1

&lt;210&gt; 1

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic oligonucleotide

&lt;400&gt; 1

gaatcctcaa attgcggcac

20

&lt;210&gt; 2

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

9151-10WO.ST25.txt

&lt;223&gt; Synthetic oligonucleotide

&lt;400&gt; 2

cagaaggtga cttggcatag

20

&lt;210&gt; 3

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic oligonucleotide

&lt;400&gt; 3

ggtgaaggtc ggagtcaacg

20

&lt;210&gt; 4

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic oligonucleotide

&lt;400&gt; 4

caaagttgtc atggatgacc

20

&lt;210&gt; 5

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic oligonucleotide

&lt;400&gt; 5

ttgcttggtc ctcctgactg

20

&lt;210&gt; 6

9151-10WO.ST25.txt

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic oligonucleotide

&lt;400&gt; 6

gatgtctggg tcttggttct

20

&lt;210&gt; 7

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic oligonucleotide

&lt;400&gt; 7

atgaaatata caagttatat cttggcttt

29

&lt;210&gt; 8

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic oligonucleotide

&lt;400&gt; 8

gatgctcttc gacctcgaaa cagcat

26

THIS PAGE BLANK (USPTO)



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number  
**WO 02/055017 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 38/12**,  
31/19

(21) International Application Number: PCT/US01/43871

(22) International Filing Date:  
19 November 2001 (19.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/718,195 21 November 2000 (21.11.2000) US

(71) Applicant (for all designated States except US): **WAKE  
FOREST UNIVERSITY** [US/US]; Medical Center  
Boulevard, Winston-Salem, NC 27157 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAMMER, Gary,  
M.** [US/US]; 2424 Sattsgate Drive, Lewisville, NC 27023  
(US). **MISHRA, Nilamadhab** [IN/US]; 1182 Stixfield  
Court, Winston-Salem, NC 27101 (US).

(74) Agent: **SIBLEY, Kenneth, D.**; Myers Bigel Sibley &  
Sajovec, P.O. Box 37428, Raleigh, NC 27627 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

Published:  
with international search report

(88) Date of publication of the international search report:  
23 January 2003

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



**WO 02/055017 A3**

(54) Title: METHOD OF TREATING AUTOIMMUNE DISEASES

(57) Abstract: A method of treating an autoimmune disease (for example, Systemic Lupus Erythematosus) comprises administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof. Methods of screening compounds useful for the treatment of autoimmune disease are also disclosed.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/43871

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 38/12, 31/19  
 US CL : 514/9, 557

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 U.S. : 514/9, 557

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 5,939,455 A (REPHAELI, A.) 17 August 1999, see entire document especially column 5, lines 24-48.	1-2, 7, 10-12 ----- 3-8, 9
X --- Y	WO 00/08048 A2 (FUJISAWA PHARMACEUTICAL CO. LTD.) 17 February 2000, see entire document, e.g., abstract.	1-3, 10-12 ----- 4-9
X --- Y	WO 93/19778 A1 (THE SCRIPPS RESEARCH INSTITUTE) 14 October 1993, see entire document, e.g. abstract.	1-2, 7, 10-12 ----- 3-6, 8-9
X --- Y	WO 00/21979 A2 (FUJISAWA PHARMACEUTICAL CO. LTD.) 20 April 2000, see entire document, e.g. abstract.	1-3, 10-12 ----- 4-9

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 August 2002 (16.08.2002)

Date of mailing of the international search report

18 SEP 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Jon P. Weber, Ph.D.

Telephone No. 703-308-0196

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6,124,495 A (NEISS et al.) 26 September 2000, see entire document, e.g. abstract.	1-2, 7, 10-12
---		-----
Y		3-6, 8-9

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/43871

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10

Remark on Protest

☐  
☐

- The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

PCT/US01/43871

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-10, drawn to a method of treating autoimmune diseases by administering a histone hyperacetylating agent.

Group II, claim(s) 11-19, drawn to a method of treating systemic lupus erythematosus by administering a histone hyperacetylating agent.

Group III, claim(s) 20-25, drawn to a method of screening compounds for inhibitors of histone deacetylase.

Group IV, claim(s) 26-29, drawn to a screening assay for treating an autoimmune disease involving whole cells, *in vivo* or *in vitro*.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I and II are drawn to methods of treatment with unstated compounds, Groups III and IV are screening methods to find compounds and do not involve methods of treatment. The treatment methods are directed to different diseases and may involve different compounds, the screening methods are drawn to different steps are practiced in different ways, with cell extracts and with whole cells or organisms.

## Continuation of B. FIELDS SEARCHED Item 3:

USPT, EPAB, JPAB, DWPI

search terms: autoimmune, lupus, rheumatoid, sjogren, polymyositis, dermatomyositis

**THIS PAGE BLANK (USP-1)**